Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Fig. 1

Accelerated titration design of the phase I part of the trial. Illustration of the accelerated titration design of the phase I part of the trial. Each box outlined in bold represents a cohort containing the indicated number of patients treated at a given dose level. Ixazomib will be administrated orally on days 1, 8, and 15 and carboplatin intravenously on days 1, 8, and 15 of a 4-week cycle. Drug dosages per dose level are given on the left side of the graph. DLT = dose-limiting toxicity; AUC = area under the curve

Back to article page